We have developed a new method to assess the binding site on alpha-bungarotoxin (alpha-BGT) for the acetylcholine receptor. It involves the covalent attachment of a palmitic acid chain to the toxin molecule, generating monopalmitoyl-alpha-bungarotoxin (PBGT) which is then immobilized on the surface of a lipid vesicle by a process of spontaneous insertion via the acyl chain into preformed unilamellar vesicles (approximately 800 A in diameter). PBGT itself is able to bind specifically to Triton X-100 solubilized acetylcholine receptors with an association constant, KA, of 5.56 X 10(6) M-1 which is approximately 20-fold lower in affinity than native alpha-BGT. Vesicle-associated PBGT binds to acetylcholine receptor enriched microsac membrane vesicles in aqueous buffer with a KA for both lipid and protein of 4.26 X 10(7) M-1. The putative site of acylation on the PBGT molecule is determined by extensive cleavage of a reduced and carboxymethylated PBGT with thermolysin. An acylated fragment is purified by hydrophobic column chromatography and identified by high-pressure liquid chromatography methods from the known primary sequence of the native toxin as a decapeptide including residues Thr47-Glu56 [C. Y. Lee convention used; see Mebs, D., Narita, K., Iwanaga, S., Samejuma, Y., & Lee, C. Y. (1971) Biochem. Biophys. Res. Commun. 44, 711-716]. Sequential hydrolysis of the fragment from the carboxy terminus with carboxypeptidase Y indicates that Lys51 is the sole site of acylation.(ABSTRACT TRUNCATED AT 250 WORDS)
No takes yet. Share an insight, caveat, or question.
Babbitt et al. (1985) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: